Multinational phase 2 study of sotorasib for previously treated KRAS p.G12C-mutated NSCLC
Dr. Ferdinandos Skoulidis
The multinational phase 2 CodeBreaK100 study evaluated sotorasib for previously treated advanced KRAS p.G12C-mutated NSCLC. Objective response was seen in 37.1% of patients, with a median duration of response 11.1 months. Disease control was seen in 80.6%. The median PFS was 6.8 months and the median OS was 12.5 months. There were no new safety signals.
